Thorsteinsdóttir S, Lemonakis K, Slørdahl TS, Rögnvaldsson S, Richardson AK, Hermansen E, Thorsen J, Schjesvold F, Moore KLF, Szabo AG, Andersen MK, Waage A, Blimark CH, Vangsted A, Nordic Myeloma Study Group (2025)
Cytogenetic abnormalities in multiple myeloma patients according to age: A real-world study by the Nordic Myeloma Study Group
Br J Haematol, 207 (4), 1638-1642
DOI 10.1111/bjh.70030, PubMed 41070698
Bertamini L, Fokkema C, Rodriguez-Otero P, van Duin M, Terpos E, D'Agostino M, van der Velden VHJ, van de Donk NWCJ, Delforge M, Driessen C, Hajek R, Einsele H, Vangsted AJ, Vieyra D, Attar RM, Sitthi-Amorn A, Carson R, Schjesvold F, Robak P, Beksac M, Spencer A, Broijl A, Cupedo T, Moreau P, Boccadoro M et al. (2025)
Circulating tumor cells predict myeloma outcomes in patients treated with daratumumab, bortezomib, lenalidomide, and dexamethasone
Blood (in press)
DOI 10.1182/blood.2025030113, PubMed 41060326
Smit AJT, Van der Maas NG, Van der Holt B, Van Norden Y, Van Werkhoven E, Vangsted AJ, Ypma PF, Visser-Wisselaar HA, Troia R, Boccadoro M, Löwenberg B, Janssen JJWM, Ossenkoppele GJ, Schjesvold F, Sonneveld P, Zweegman S, Versluis J, Cornelissen JJ (2025)
The added value of Bayesian interim analysis in randomized phase II and phase III clinical trials in hemato-oncology
Haematologica (in press)
DOI 10.3324/haematol.2025.288675, PubMed 41035401
